Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis—Reanalysis of Fibrosis Stage 2-3 Subset.
Resmetirom safely improves liver scarring and metabolic markers in mid-stage MASH disease, confirming its value for approved patients.
This post-hoc reanalysis of 917 F2-F3 fibrosis patients from MAESTRO-NASH confirms resmetirom's significant efficacy and safety within its FDA-approved label population, showing consistent MASH resolution and fibrosis improvement with LDL reduction and no new safety signals at 52 weeks. Results directly reinforce the clinical evidence base for resmetirom prescribing in the approved F2-F3 MASH indication.
What the study was
- Study design
- Post-hoc subset analysis of Phase 3 RCT (MAESTRO-NASH)
- Population
- Adults with MASH and F2-F3 fibrosis (approved label population, n=917)
- Sample size
- 917
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Alimentary Pharmacology and Therapeutics
Why it surfaced
Post-hoc Phase 3 confirmatory analysis for an FDA-approved drug in the exact labeled population; directly supports clinical decision-making for MASH prescribers.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.